Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062987 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| SCHEMBL22407293 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| Aspartic Acid SCHEMBL5964784 | 0.79 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL13319909 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL5290687 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL28471680 | 0.74 | GRIA1 (0.47) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL4437211 | 0.72 | GRIA1 (0.36) | GRIA1GRIA3GRIA2GRIA4GAA | |
| Propionic Acid SCHEMBL4774389 | 0.67 | FFAR3 (0.37) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| (S)-Ampa SCHEMBL667915 | 0.67 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL6809086 | 0.67 | CACNA1F (0.33) | CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119881321-A | Application of AMPAR protein group in response to terahertz waves | 中国人民解放军军事科学院军事医学研究院 | 2025-04-25 | — | — | CN | claimed |
| EP-4132496-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF STRESS-INDUCED FEAR, DEPRESSIVE-LIKE AND ANXIETY- LIKE BEHAVIOR | The Trustees of Columbia University in the City of New York (US) | 2023-02-15 | — | — | EP | claimed |
| EP-3915120-A1 | PHARMACOGENOMIC DECISION SUPPORT FOR MODULATORS OF THE NMDA, GLYCINE, AND AMPA RECEPTORS | The Regents of the University of Michigan (US) | 2021-12-01 | — | — | EP | claimed |
| WO-2020219975-A1 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | CYTOSOLVE, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| US-10338068-B2 | Selection of biological objects | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-07-02 | — | — | US | claimed |
| US-20190133975-A1 | TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS | STC UNM (US) | 2019-05-09 | — | — | US | claimed |
| US-20160193161-A1 | TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2016-07-07 | — | — | US | claimed |
| WO-2015023830-A1 | TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS | STC.UNM (US) | 2015-02-19 | — | — | WO | claimed |
| JP-2012500283-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2334185-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | Knopp Neurosciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022140-A1 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE | KNOPP NEUROSCIENCES, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-7192931-B2 | Treatment of demyelinating diseases | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-03-20 | — | — | US | claimed |
| EP-1359933-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | Neuronz Limited (NZ) | 2003-11-12 | — | — | EP | claimed |
| WO-2002030448-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030447-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| JP-11279158-A | — | — | None | — | — | JP | disclosed |
| CN-122070289-A | Hydroxynorketamine analogues and uses thereof | 灵飞制药公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-1996008494-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
| US-5364876-A | Tranquilizers, analgesics, learning enhancement | GUILFORD PHARMACEUTICALS INC. (US) | 1994-11-15 | — | — | US | disclosed |
| WO-1993004687-A1 | USE OF PREGNENOLONE SULFATE AND DERIVATIVES FOR THE TREATMENT OF CNS DISEASES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190133975-A1 | TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS | GPR119, OGDH, INA | GRIA1 294/4885GRIA3 66/4885GRIA2 391/4885 |
| US-20160193161-A1 | TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS | GPR119, OGDH, INA | GRIA1 294/4885GRIA3 66/4885GRIA2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.